Dysregulated MiRNAs As Biomarkers and Therapeutical Targets in Neurodegenerative Diseases

Overview

Journal J Pers Med

Date 2022 May 28

PMID 35629192

Authors

Giulia Gentile

Giovanna Morello

Valentina La Cognata

Maria Guarnaccia

Francesca Luisa Conforti

Sebastiano Cavallaro

Affiliations

Soon will be listed here.

Abstract

Alzheimer's disease (AD), Parkinson's disease (PD), and Amyotrophic Lateral Sclerosis (ALS) are representative neurodegenerative diseases (NDs) characterized by degeneration of selective neurons, as well as the lack of effective biomarkers and therapeutic treatments. In the last decade, microRNAs (miRNAs) have gained considerable interest in diagnostics and therapy of NDs, owing to their aberrant expression and their ability to target multiple molecules and pathways. Here, we provide an overview of dysregulated miRNAs in fluids (blood or cerebrospinal fluid) and nervous tissue of AD, PD, and ALS patients. By emphasizing those that are commonly dysregulated in these NDs, we highlight their potential role as biomarkers or therapeutical targets and describe the use of antisense oligonucleotides as miRNA therapies.

Citing Articles

MiRNAs as major players in brain health and disease: current knowledge and future perspectives.

Kapplingattu S, Bhattacharya S, Adlakha Y Cell Death Discov. 2025; 11(1):7.

PMID: 39805813 PMC: 11729916. DOI: 10.1038/s41420-024-02283-x.

Upregulated miR-10b-5p as a potential miRNA signature in amyotrophic lateral sclerosis patients.

Dash B, Freischmidt A, Helferich A, Ludolph A, Andersen P, Weishaupt J Front Cell Neurosci. 2024; 18:1457704.

PMID: 39588282 PMC: 11586771. DOI: 10.3389/fncel.2024.1457704.

MicroRNAs regulating autophagy: opportunities in treating neurodegenerative diseases.

Mohseni M, Behzad G, Farhadi A, Behroozi J, Mohseni H, Valipour B Front Neurosci. 2024; 18:1397106.

PMID: 39582602 PMC: 11582054. DOI: 10.3389/fnins.2024.1397106.

Ethanol modulates astrocyte activation and neuroinflammation via miR-339/NLRP6 inflammasome signaling.

Singh S, Kannan M, Oladapo A, Deshetty U, Ray S, Buch S Free Radic Biol Med. 2024; 226:1-12.

PMID: 39522566 PMC: 11688707. DOI: 10.1016/j.freeradbiomed.2024.11.014.

Bibliometric analysis of microRNAs and Parkinson's disease from 2014 to 2023.

Chen L, Chen J, Weng W, Wu M, Zhou X, Yan P Front Neurol. 2024; 15:1466186.

PMID: 39385824 PMC: 11462628. DOI: 10.3389/fneur.2024.1466186.

References

DErchia A, Gallo A, Manzari C, Raho S, Horner D, Chiara M . Massive transcriptome sequencing of human spinal cord tissues provides new insights into motor neuron degeneration in ALS. Sci Rep. 2017; 7(1):10046. PMC: 5577269. DOI: 10.1038/s41598-017-10488-7. View

Saucier D, Wajnberg G, Roy J, Beauregard A, Chacko S, Crapoulet N . Identification of a circulating miRNA signature in extracellular vesicles collected from amyotrophic lateral sclerosis patients. Brain Res. 2018; 1708:100-108. DOI: 10.1016/j.brainres.2018.12.016. View

Kim W, Lee Y, McKenna N, Yi M, Simunovic F, Wang Y . miR-126 contributes to Parkinson's disease by dysregulating the insulin-like growth factor/phosphoinositide 3-kinase signaling. Neurobiol Aging. 2014; 35(7):1712-21. PMC: 3991567. DOI: 10.1016/j.neurobiolaging.2014.01.021. View

Rinchetti P, Rizzuti M, Faravelli I, Corti S . MicroRNA Metabolism and Dysregulation in Amyotrophic Lateral Sclerosis. Mol Neurobiol. 2017; 55(3):2617-2630. DOI: 10.1007/s12035-017-0537-z. View

Mullard A . ALS antisense drug falters in phase III. Nat Rev Drug Discov. 2021; 20(12):883-885. DOI: 10.1038/d41573-021-00181-w. View

Wang X, Liu D, Huang H, Wang Z, Hou T, Yang X . A Novel MicroRNA-124/PTPN1 Signal Pathway Mediates Synaptic and Memory Deficits in Alzheimer's Disease. Biol Psychiatry. 2017; 83(5):395-405. DOI: 10.1016/j.biopsych.2017.07.023. View

Lukiw W, Zhao Y, Cui J . An NF-kappaB-sensitive micro RNA-146a-mediated inflammatory circuit in Alzheimer disease and in stressed human brain cells. J Biol Chem. 2008; 283(46):31315-22. PMC: 2581572. DOI: 10.1074/jbc.M805371200. View

Serpente M, Bonsi R, Scarpini E, Galimberti D . Innate immune system and inflammation in Alzheimer's disease: from pathogenesis to treatment. Neuroimmunomodulation. 2014; 21(2-3):79-87. DOI: 10.1159/000356529. View

Schlaudraff F, Grundemann J, Fauler M, Dragicevic E, Hardy J, Liss B . Orchestrated increase of dopamine and PARK mRNAs but not miR-133b in dopamine neurons in Parkinson's disease. Neurobiol Aging. 2014; 35(10):2302-15. PMC: 4099518. DOI: 10.1016/j.neurobiolaging.2014.03.016. View

10.

Zhang X, Yang R, Hu B, Lu P, Zhou L, He Z . Reduced Circulating Levels of miR-433 and miR-133b Are Potential Biomarkers for Parkinson's Disease. Front Cell Neurosci. 2017; 11:170. PMC: 5481393. DOI: 10.3389/fncel.2017.00170. View

11.

Hu Y, Zhang Y, Wang H, Ren R, Cui H, Huang W . miR-425 deficiency promotes necroptosis and dopaminergic neurodegeneration in Parkinson's disease. Cell Death Dis. 2019; 10(8):589. PMC: 6683159. DOI: 10.1038/s41419-019-1809-5. View

12.

Lang Y, Li Y, Yu H, Lin L, Chen X, Wang S . HOTAIR drives autophagy in midbrain dopaminergic neurons in the substantia nigra compacta in a mouse model of Parkinson's disease by elevating NPTX2 miR-221-3p binding. Aging (Albany NY). 2020; 12(9):7660-7678. PMC: 7244061. DOI: 10.18632/aging.103028. View

13.

Zhao J, Yang M, Li Q, Pei X, Zhu X . miR-132-5p regulates apoptosis and autophagy in MPTP model of Parkinson's disease by targeting ULK1. Neuroreport. 2020; 31(13):959-965. DOI: 10.1097/WNR.0000000000001494. View

14.

Puthiyedth N, Riveros C, Berretta R, Moscato P . Identification of Differentially Expressed Genes through Integrated Study of Alzheimer's Disease Affected Brain Regions. PLoS One. 2016; 11(4):e0152342. PMC: 4822961. DOI: 10.1371/journal.pone.0152342. View

15.

Gundersen V . Protein aggregation in Parkinson's disease. Acta Neurol Scand Suppl. 2010; (190):82-7. DOI: 10.1111/j.1600-0404.2010.01382.x. View

16.

Liu S, Fan M, Zheng Q, Hao S, Yang L, Xia Q . MicroRNAs in Alzheimer's disease: Potential diagnostic markers and therapeutic targets. Biomed Pharmacother. 2022; 148:112681. DOI: 10.1016/j.biopha.2022.112681. View

17.

La Cognata V, Morello G, Cavallaro S . Omics Data and Their Integrative Analysis to Support Stratified Medicine in Neurodegenerative Diseases. Int J Mol Sci. 2021; 22(9). PMC: 8125201. DOI: 10.3390/ijms22094820. View

18.

Vilardo E, Barbato C, Ciotti M, Cogoni C, Ruberti F . MicroRNA-101 regulates amyloid precursor protein expression in hippocampal neurons. J Biol Chem. 2010; 285(24):18344-51. PMC: 2881760. DOI: 10.1074/jbc.M110.112664. View

19.

Alieva A, Filatova E, Karabanov A, Illarioshkin S, Limborska S, Shadrina M . miRNA expression is highly sensitive to a drug therapy in Parkinson's disease. Parkinsonism Relat Disord. 2014; 21(1):72-4. DOI: 10.1016/j.parkreldis.2014.10.018. View

20.

Zhu H, Wang L, Wang M, Song B, Tan S, Teng J . MicroRNA-195 downregulates Alzheimer's disease amyloid-β production by targeting BACE1. Brain Res Bull. 2012; 88(6):596-601. DOI: 10.1016/j.brainresbull.2012.05.018. View